lonafarnib has been researched along with lapatinib in 1 studies
Studies (lonafarnib) | Trials (lonafarnib) | Recent Studies (post-2010) (lonafarnib) | Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) |
---|---|---|---|---|---|
224 | 34 | 90 | 1,919 | 305 | 1,442 |
Protein | Taxonomy | lonafarnib (IC50) | lapatinib (IC50) |
---|---|---|---|
Bile salt export pump | Homo sapiens (human) | 7.375 | |
Epidermal growth factor receptor | Homo sapiens (human) | 0.0827 | |
Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | 0.0537 | |
Platelet-derived growth factor receptor beta | Homo sapiens (human) | 8.5 | |
D(1A) dopamine receptor | Sus scrofa (pig) | 0.06 | |
Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 1 | |
Receptor tyrosine-protein kinase erbB-4 | Homo sapiens (human) | 0.1659 | |
Alpha-1A adrenergic receptor | Sus scrofa (pig) | 0.06 | |
Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | 3.2 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Dowlati, A; Halmos, B; Kern, JA; Kluge, A; Nethery, D | 1 |
1 other study(ies) available for lonafarnib and lapatinib
Article | Year |
---|---|
SCH66336, inhibitor of protein farnesylation, blocks signal transducer and activators of transcription 3 signaling in lung cancer and interacts with a small molecule inhibitor of epidermal growth factor receptor/human epidermal growth factor receptor 2.
Topics: Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Colorimetry; Drug Synergism; Flow Cytometry; Humans; Indicators and Reagents; Lapatinib; Mutation; Oncogene Protein v-akt; Piperidines; Prenylation; Pyridines; Quinazolines; Receptor, ErbB-2; Signal Transduction; STAT3 Transcription Factor | 2008 |